Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Radioactive Gold Nanoparticles Shrink Prostate Tumors in Mouse Model

By LabMedica International staff writers
Posted on 02 Aug 2012
Radioactive gold nanoparticles conjugated to a compound that specifically binds to a receptor present on prostate cancer cells have been used to halt the growth of aggressive prostate tumors in a mouse xenograft model.

Investigators at the University of Missouri (Columbia, USA) created targeted radioactive nanoparticles by conjugating prostate tumor specific epigallocatechin-gallate (EGCg) to gold nanoparticles derived from the Au-198 isotope. More...
EGCg binds with excellent affinity to Laminin67R receptors, which are over expressed in prostate tumor cells while Au-198, which has a half-life of 2.7 days, emits a deadly beta particle that is able to penetrate approximately 11 mm in tissue (approximately 1100 cell diameters). This range is sufficiently long to deliver a lethal radiation dose to cells within the prostate gland and short enough to minimize the radiation dose to adjacent critical tissues.

Radioactive gold nanoparticles were administered to SCID mice carrying prostate cancer PC-3 xenografts. Results published in the July 16, 2012, online edition of the journal Proceedings of the National Academy of Sciences of the USA (PNAS) revealed that approximately 72% of the 198AuNP-EGCg nanoparticles became sequestered in tumors 24 hours after intratumoral administration. Therapeutic studies showed 80% reduction of tumor volumes after 28 days, demonstrating significant inhibition of tumor growth compared to controls.

"In our study, we found that a special compound in tea was attracted to tumor cells in the prostate," said senior author Dr. Kattesh Katti, professor of radiology and at the University of Missouri. "When we combined the tea compound with radioactive gold nanoparticles, the tea compound helped "deliver" the nanoparticles to the site of the tumors and the nanoparticles destroyed the tumor cells very efficiently."

Related Links:

University of Missouri




Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.